viewOpen Orphan PLC

Open Orphan expects early adopters to come aboard platform later this year

A revenue share scheme will be used to encourage patients with rare and orphan conditions to share their health data.

Open Orphan - Open Orphans expects early adopters to come aboard its platform later this year
Platform will give access to rare diseases experts

Rare disease specialist Open Orphan PLC (LON:OPRH) expects to announce the first early adopters of its genomic health data platform later this year.

Open Orphan carried out a reverse takeover of Venn Life Sciences in June with the aim of creating Europe's largest databases of rare disease patients through its two digital platforms.

In its first statement since the deal, Open Orphan said it has started to approach pharma companies and patient advocacy groups to help source rare disease patient genomic data.

A revenue share scheme will be used to encourage patients with rare and orphan conditions to share their health data.

Open Orphan’s second platform (virtual rep) ais to give pharmaceutical companies access to 4,000 key opinion leaders and physicians across Europe with a focus on orphan drugs.

In due course, the platform will enable Open Orphan to promote client services to its extensive list of key opinion leaders and physicians.

Cathal Friel, chief executive, said the group also had an extensive acquisition pipeline to help grow both platforms.

Operating losses in the half-year to June were €1.8mln on revenues of €5.8mln, though these relate to the old Venn Life business.

Open Orphan raised £4.5mln in June to refinance the business.

Quick facts: Open Orphan PLC

Price: 13.945 GBX

Market: AIM
Market Cap: £92.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Open Orphan: New deal with top-three pharma company is 'evidence validation...

Proactive Research analyst Emma Ulker says the news this morning that Open Orphan PLC (LON:ORPH) subsidiary hVIVO has signed a £4mln contract with an unnamed top-three global pharma company is evidence that the validation is building as well as recognition amongst larger players in the industry....

1 day, 22 hours ago

2 min read